Clinical Trials

Protocol 10476: A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers (CTMS# 22-0023)

Cancer Type

Liver and Hepatobilary Cancer

ClinicalTrials.gov Identifier

ClinicalTrials.gov registration not required

Principal Investigator

Sukeshi Arora MD

For more information about this study
View Details

About This Study

This phase II trial investigates the effect of combining two immune therapies, atezolizumab and CDX-1127 (varlilumab), with or without cobimetinib, in treating patients with biliary tract cancer that cannot be removed by surgery (unresectable).